Responses
Regular and young investigator award abstracts
Immune-stimulants and immune modulators
552 SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models
Compose a Response to This Article
Other responses
No responses have been published for this article.
